TVGNW
MaterialsTevogen Bio Holdings Inc - Warrants (14/02/2029)
$0.04+0.00 (+12.66%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving TVGNW Today?
No stock-specific AI insight has been generated for TVGNW yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.03$0.08
$0.04
Fundamentals
Market Cap—
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume—
Avg Volume (10D)—
Shares Outstanding—
TVGNW News
20 articles- Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue GrowthYahoo Finance·Mar 26, 2026
- Tevogen Regains Compliance with Nasdaq Minimum Bid Price RequirementYahoo Finance·Mar 25, 2026
- Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)Yahoo Finance·Mar 18, 2026
- Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-QYahoo Finance·Nov 14, 2025
- Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVIDYahoo Finance·Nov 5, 2025
- Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash BurnYahoo Finance·Nov 3, 2025
- Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent ProgressYahoo Finance·Oct 29, 2025
- Tevogen Updates on TVGN 489 Following Growing Long COVID Patient InterestYahoo Finance·Oct 15, 2025
- Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data ExpansionYahoo Finance·Sep 25, 2025
- Tevogen highlights potential role of TVGN 489 on impact of Long COVIDYahoo Finance·Sep 24, 2025
- Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVIDYahoo Finance·Sep 23, 2025
- Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million AmericansYahoo Finance·Sep 19, 2025
- Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in BostonYahoo Finance·Sep 10, 2025
- Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B InfectionYahoo Finance·Sep 9, 2025
- Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell PlatformYahoo Finance·Sep 8, 2025
- Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and LymphomasYahoo Finance·Sep 4, 2025
- Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2Yahoo Finance·Sep 3, 2025
- Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation DisclosureYahoo Finance·Aug 27, 2025
- Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company’s Mission of Health EquityYahoo Finance·Aug 26, 2025
- Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained PositionsYahoo Finance·Aug 25, 2025
All 20 articles loaded
Price Data
Open$0.00
Previous Close$0.04
Day High$0.00
Day Low$0.00
52 Week High$0.08
52 Week Low$0.03
52-Week Range
$0.03$0.08
$0.04
Fundamentals
Market Cap—
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume—
Avg Volume (10D)—
Shares Outstanding—
About Tevogen Bio Holdings Inc - Warrants (14/02/2029)
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. The company is headquartered in Warren, New Jersey.
MaterialsBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
CIK—
Composite FIGI—
Share Class FIGI—